✦ LIBER ✦

Effect of long-term belimumab treatment on b cells in systemic lupus erythematosus: Extension of a phase II, double-blind, placebo-controlled, dose-ranging study

✍ Scribed by Annett M. Jacobi; Weiqing Huang; Tao Wang; William Freimuth; Inaki Sanz; Richard Furie; Meggan Mackay; Cynthia Aranow; Betty Diamond; Anne Davidson

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 593 KB
Volume: 62
Category: Article
ISSN: 0004-3591
DOI: 10.1002/art.27189

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II, randomized, double-blind, pl

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus

✍ Wallace, Daniel J. ;Stohl, William ;Furie, Richard A. ;Lisse, Jeffrey R. ;McKay, 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 372 KB 👁 2 views

## Abstract ## Objective To assess the safety, tolerability, biologic activity, and efficacy of belimumab in combination with standard of care therapy (SOC) in patients with active systemic lupus erythematosus (SLE). ## Methods Patients with a Safety of Estrogens in Lupus Erythematosus: National

Reduced B lymphocyte and immunoglobulin

Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: Results of a multicenter, phase ib, double-blind, placebo-controlled, dose-escalating trial

✍ Maria Dall'Era; Eliza Chakravarty; Daniel Wallace; Mark Genovese; Michael Weisma 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 200 KB 👁 2 views